GlobeNewswire

YPO Global Pulse Survey: Which Disruptive Technologies Command Attention and Investment of CEOs Globally, Now?

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=bafdfc27-f81f-4632-86ba-c6cf838ac917&maxHeight=150&maxWidth=150

Survey of 10 disruptive technologies highlights those most likely to impact businesses and investments in the next 12 months

DALLAS, April 03, 2018 (GLOBE NEWSWIRE) -- YPO, the premier chief executive leadership organization in the world, announced today the results of the March 2018 YPO Global Pulse Survey, revealing that chief executives across the world are focused on core business technologies, such as cloud computing, business intelligence (BI) and cybersecurity, whilst adoption and investment of emerging technologies such as blockchain, artificial intelligence (AI) and cryptocurrency are likely to be sector-driven.

Disruptive Technologies Attracting CEO Attention and Likely Investment Globally:

  • Cloud computing is a key priority for chief executives globally - more than two-thirds (68%) of chief executives report that cloud computing is likely to impact their business in the next 12 months, and 62% state that they are likely to invest in cloud-based technologies.
     
  • Business Intelligence (BI) has the attention of CEOs - 65% of chief executives surveyed expect BI to impact their organizations and more than half (56%) are likely to invest in business intelligence in the coming 12 months.
     
  • Cybersecurity is a disruptive technology that chief executives have prioritized given the scale and severity of recent high-profile consumer data breaches, 53% of chief executives are expecting cybersecurity to impact their business and 47% state that they are likely to invest in cybersecurity technology in the coming year.

"What I'm hearing from YPO global business leaders right now is that digital transformation remains at the very top of their priorities in 2018. Several disruptive technologies are expected to garner widespread attention and investment this year, such as cloud computing, cybersecurity, business intelligence and mobile payment applications," said Scott Mordell, CEO of YPO. "YPO members are embracing technology to address regulatory requirements, harness business data for improved efficiency and increased financial performance, and to match consumer demand for new and innovative ways to interact with their businesses."

Despite Expected Disruption, CEOs Less Likely to Invest in These Technologies in the Next Year:

  • Although virtual reality (VR)/Augmented Reality (AR) are widely noted as technologies likely to impact most industries, most CEOs surveyed are not actively investing in those technologies yet. However, within architecture and engineering sectors, 83% of business leaders expect VR to impact their business and 64% plan to invest in it over the next 12 months, as compared to only 23% of all chief executives surveyed willing to invest in these technologies now.
  • Similarly, artificial intelligence (AI) is perceived as likely to impact businesses, but CEOs are less likely to invest in AI this year as cloud computing, business intelligence, cybersecurity and digital/mobile payment applications, which are commanding more immediate attention and likely candidates for investment in the next 12 months.
  • CEOs are least familiar with chatbot technology, followed by blockchain and cryptocurrency among the 10 disruptive technologies surveyed. As a result, they tend to discount the likelihood of disruption to their businesses from these new emerging technologies and show much lower interest in investing in these technologies this year.

Disruptive Technology Investment Driven by Specific Industry Sectors

The levels of familiarity and interest in many disruptive technologies are determined by industry.  For instance, although there has been much media attention and discussion around blockchain and cryptocurrency, most CEOs do not see either of those technologies as particularly likely to impact their businesses, and are not likely to invest in those technologies. However, blockchain has gained the attention and investment of CEOs in the financial services sector.

  • More than half (58%) of chief executives in financial services expect blockchain technology to impact their organization over the next 12 months, and as many as 40% expect to make investments in the technology.  
     
  • The Internet of Things (IoT) is cited as a key technology area by business leaders within the telecom, architecture, engineering and technology sectors. More than three quarters (78%) of chief executives in telecoms expect IoT to impact their business and almost all of them (96%) expect to make investments in IoT over the next 12 months.

"The findings of the YPO Global Pulse reveal that the short-term business impact and investment strategy associated with a particular technology is largely dependent on the specific industry in which you operate," noted Scott Mordell, CEO of YPO. "It will be fascinating to see how priorities and focus change over the next year as disruptive technologies such as AI and virtual reality become more mainstream."

YPO Global Pulse® Survey

The YPO Global Pulse provides insight into the perspectives of chief executives around the world on topics that influence businesses, leadership and impact. The March 2018 Global Pulse survey results provide key insight into the understanding, attitudes and investment plans of chief executives around the world, regarding the 10 disruptive technologies that are attracting attention right now. The March 2018 YPO Global Pulse survey provides perspectives from 842 YPO members, from 15 different regions of the world and across 28 industry sectors. Visit www.ypo.org/globalpulse for more information about the survey methodology and results.

About YPO

The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit YPO.org.

Contact:
YPO 
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298
press@ypo.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum